Cat. No.: DIA-0230797
Product Information | |
---|---|
CAS No. | 1089283-49-7 |
Synonyms | GSK 4529 |
Formula | C44H47F2N9O5S |
Molecular Weight | 851.96 |
SMILES | CCC1=CC(=C(OC)C=C1N2CCC(CC2)N3CCN(CC3)[S](C)(=O)=O)NC4=NC(=CC=N4)C5=C(N=C6C=CC=C[N]56)C7=CC(=C(OC)C=C7)C(=O)NC8=C(F)C=CC=C8F |
Product Description | GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc. |
Format & Storage | |
---|---|
Purity | > 98% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.